Use of Baricitinib in a patient with treatment-resistant pyoderma gangrenosum

SAGE Open Med Case Rep. 2024 Mar 23:12:2050313X241235444. doi: 10.1177/2050313X241235444. eCollection 2024.

Abstract

Pyoderma gangrenosum is a rare inflammatory neutrophilic disorder with no uniformly effective therapy and limited high-level evidence. Common therapies include immunosuppressive and immunomodulating agents. There exist several case series using small molecules as treatment modalities. Here, we report a case of a 78-year-old female with a diagnosis of pyoderma gangrenosum and metastatic high-grade serous carcinoma of the ovary who was treated with Baricitinib 4 mg daily in combination with a tapering course of prednisone after failing other conventional therapies including systemic corticosteroids, colchicine, and intravenous immunoglobulin.

Keywords: Immunology; inflammatory dermatoses; wound.

Publication types

  • Case Reports